Clinical Trials Logo

Filter by:
NCT ID: NCT01324076 Recruiting - Liver Cancer Clinical Trials

Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Start date: November 2010
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether transarterial chemoembolization using doxorubicin-eluting beads is more effective when given with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. PURPOSE: This randomized phase III trial is studying giving transarterial chemoembolization using doxorubicin-eluting beads and sorafenib tosylate to see how well it works compared with giving transarterial chemoembolization using doxorubicin-eluting beads and a placebo in treating patients with liver cancer that cannot be removed by surgery.

NCT ID: NCT01320345 Recruiting - Clinical trials for Type 1 Diabetes Mellitus

The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

FAME 1 EYE
Start date: November 3, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative diabetic retinopathy.

NCT ID: NCT01320319 Recruiting - Colorectal Cancer Clinical Trials

Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients

EPA-colo
Start date: March 2011
Phase: Phase 2/Phase 3
Study type: Interventional

Primary Aim is to test the Hypothesis: Nutritional supplementation with 960mg EPA three times a day positively affects muscle function and mass (assessed by muscle biopsies, assays of cellular aerobic function and DEXA scan) and inflammation (measuring cellular markers of inflammation) in patients undergoing resection of colorectal cancers. The secondary aim is to evaluate aerobic performance assessed by cardiopulmonary exercise testing (CPEX) and perioperative outcome in patients with colorectal cancer post surgical resection.

NCT ID: NCT01316744 Recruiting - Cancer Clinical Trials

Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain

Start date: April 2009
Phase: Phase 3
Study type: Interventional

RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given together with the best pain management in treating neuropathic pain in patients with cancer. PURPOSE: This randomized phase III trial is studying ketamine hydrochloride given together with the best pain management to see how well it works compared with giving a placebo together with the best pain management in treating cancer patients with neuropathic pain.

NCT ID: NCT01307553 Recruiting - Clinical trials for Diseased Saphenous Vein Grafts

Over and Under/Aneugraft Pericardium Covered Stent Long Term Follow up Registry

Sleeve III
Start date: September 2010
Phase: N/A
Study type: Observational

The purpose of this study is to track the clinical safety and effectiveness of the Pericardium Covered Stent in "real world" use.

NCT ID: NCT01303887 Recruiting - Follicular Lymphoma Clinical Trials

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

PACIFICO
Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether R-FC is more beneficial that R-CVP in the treatment of older patients (aged 60 or over) with Follicular Lymphoma (FL).

NCT ID: NCT01301196 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Reducing Sedentary Behaviour in Young Adults at Risk of Diabetes

STAND
Start date: October 2010
Phase: N/A
Study type: Interventional

Excessive periods of time spent sitting may be a risk factor for diabetes. Current lifestyles encourage large amounts of sitting (sedentary behaviour) through increasing car use, computers, and appealing screen-based home entertainment systems. Methods to help change such behaviours are now needed, particularly for those with a high risk of developing a chronic disease, such as diabetes. The investigators propose to decrease sedentary behaviour in a multi-ethnic group of young adults at risk of diabetes through an educational intervention (attending a workshop and having prompts). If successful, this could have significant public health benefits given the widespread nature of sedentary behaviour.

NCT ID: NCT01299168 Recruiting - Clinical trials for Incorporate Molecular Diagnosis Into Diagnostic Standards

Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation

Start date: May 2011
Phase:
Study type: Observational

The current standard for biopsy-based diagnoses of dysfunction of kidney transplants is the Banff Classification which represents arbitrary international consensus. Recent data-driven approaches using molecular and conventional technologies indicate that mere consensus produces frequently incorrect diagnoses with potential harm to patients due to inappropriate treatment. To address this unmet need and improve diagnostics in the area of organ transplantation, the Alberta Transplant Applied Genomics Centre (ATAGC) has developed a new diagnostic system that combines the molecular and histopathological features of transplant biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. The present study will validate and refine this system in 500 prospectively unselected biopsies for clinical indications from American, Canadian and European centres in addition to 300 biopsies already collected. Due to a considerable interest and support from participating Centers, the study is further extended to 1500 prospective biopsies. Thus this is the extension of the INTERCOM study (INTERCOMEX). In addition to demonstrating the feasibility and value of this System in routine patient care and clinical trials, the study will develop and optimize a transparent and user-friendly reporting format to communicate this information to clinicians and obtain detailed feedback on how this system can best improve patient care.

NCT ID: NCT01285479 Recruiting - Multiple Sclerosis Clinical Trials

The Gilenya Pregnancy Registry

Start date: October 15, 2011
Phase:
Study type: Observational [Patient Registry]

The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations.

NCT ID: NCT01268722 Recruiting - Clinical trials for Chronic Total Occlusion of Artery of the Extremities

Balloon Angioplasty Versus Primary Stenting for the Treatment of Femoropopliteal Artery Chronic Total Occlusions

FACTORY
Start date: December 2010
Phase: Phase 3
Study type: Interventional

This is a multicenter double-arm randomized trial investigating plain balloon angioplasty versus primary placement of self-expanding nitinol stents after endovascular recanalization of femoral CTOs. Study will recruit up to 200 patients to be adequately powered for detection of a significant difference in vessel patency after 1 year.